United States: The EpiPen Controversy Signals Intensifying Scrutiny Of Drug Classification Under Medicaid Rebate Program

Price increases threatening the availability of EpiPen® and EpiPen Jr® Auto-Injectors ("EpiPen") have touched off the latest firestorm over drug pricing. Lost amid the public outcry, however, is a thorny regulatory issue: EpiPen's classification as a generic drug for purposes of the Medicaid Drug Rebate Program ("MDRP"). Resolution of the classification issue carries significant risk for segments of the drug industry.

EpiPen's Backstory and the MDRP

EpiPen is an epinephrine auto-injector for emergency treatment of anaphylaxis. The U.S. Food and Drug Administration ("FDA") approved EpiPen in December 1987 and currently lists it in the FDA National Drug Code Directory under a New Drug Application by its manufacturer, Mylan Specialty L.P. ("Mylan"). Following year-over-year price increases since Mylan acquired EpiPen in 2007, members of Congress now claim EpiPen originally was misclassified as a generic drug under the MDRP. Drug classification is significant, because generic drugs are subject to a substantially lower rebate than their brand counterparts, as explained in more detail below.

By way of background, Congress established the MDRP in 1990 as part of the Omnibus Budget Reconciliation Act, legislation enacted to help control the cost of Medicaid prescription drug coverage. For a drug to be eligible for Medicaid reimbursement, its manufacturer must enter an agreement with the U.S. Department of Health and Human Services ("HHS") to pay rebates to states based on the utilization of the drug. The agreement requires manufacturers to report, on a quarterly basis, statutorily defined pricing information (i.e., Average Manufacturer Price ("AMP") and best price) that is used to calculate the rebate the manufacturer must pay. Currently, the rebate for single source and innovator multiple source drugs is the greater of 23.1% of the AMP per unit or the difference between the AMP and the best price per unit. For non-innovator, multiple source drugs, the rebate is 13% of the AMP per unit. Further, since the passage of the Affordable Care Act in 2010, generic drugs (i.e., non-innovator multiple-source drugs) been exempt from the additional inflationary rebate applied to brand drugs for which AMP increases faster than the rate of inflation.

In October 1997, the Health Care Financing Administration ("HCFA"), now known as the Centers for Medicare & Medicaid Services ("CMS"), conferred with FDA "in order to determine the Drug Category . . . to use when reporting [EpiPen]" to the MDRP. "Because these products are included in a package with a new delivery system, they are listed by the FDA under an NDA (New Drug Application)," HCFA stated; however, "[t]he products themselves . . . are listed under an ANDA (Abbreviated New Drug Application) because they are very old products and made by many generic drug companies." HCFA concluded, "even though the current NDCs of these products . . . are listed under an NDA, it is entirely fitting and proper . . . to report them to the Drug Rebate Program with a Drug Category of 'N' (Non-innovator, Multiple Source) and be subject to the lowest rebate amount of 11% of quarterly AMP." See id. (emphasis added). EpiPen has since been designated as a non-innovator drug in calculating federal rebates.

Legislators have seized on the 1997 letter, voicing frustration directly to HHS and CMS. On August 30, 2016, a bipartisan group of U.S. Senators called on CMS "to explain why EpiPens are considered a non-innovator multiple source drug rather than an innovator multiple source drug." On September 2, Ranking Members of the Senate Finance Committee and House Energy & Commerce Committee wrote to HHS complaining EpiPen's generic classification "is inconsistent with how the FDA lists the EpiPen®, as well as how Medicare treats these products for purposes of the Medicare Part D prescription drug program. As a result, it appears that Medicaid may have been grossly overpaying for EpiPen® and its related products due to Mylan's misclassification," because of lower Medicaid rebate payments on EpiPen.

EpiPen's Regulatory Conundrum

Whether and how EpiPen actually was misclassified as a generic drug presents a novel and important legal question. On the one hand, EpiPen's active pharmaceutical ingredient ("API"), epinephrine (or adrenaline), is a non-innovator medication and hormone approved for sale under an abbreviated NDA in May 1984. On the other hand, Mylan's EpiPen is marketed under an NDA because it uses a patented auto-injector to intravenously deliver a measured dose of epinephrine.

And EpiPen hardly is alone. As The New York Times reported before the Labor Day holiday, "[m]any other old medications have been delivered in new packages in recent years." These include asthma inhalers and insulin injectors, plus emergency rescue drugs similar to EpiPen like GlucaGen ® (indicated for treatment of severe hypoglycemia) and Narcan® (used for emergency treatment of opioid overdose), both of which utilize generic APIs in dosage forms administered by intramuscular injection using new types of auto-injectors. How should these products and others like them be classified for purposes of the MDRP?

According to CMS's new Medicaid-covered outpatient drugs final rule, "[a]ll drugs marketed under an NDA, other than an ANDA, regardless of when they were approved, should be categorized as single source or innovator multiple source drugs, unless CMS determines that a narrow exception applies as discussed [] pursuant to this final rule." 81 Fed. Reg. 5170, 5193 (Feb. 1, 2016) (emphasis added). Specifically, CMS acknowledged "[t]here may be very limited circumstances where, for the purposes of the Medicaid Drug Rebate (MDR) program, certain drugs might be more appropriately treated as if they were approved under an ANDA and classified as a non-innovator multiple source drug." Id. at 5191. For example,

certain parenteral drugs in plastic immediate containers, for which FDA required that an NDA be filed, might be more appropriately treated, for purposes of the MDR program, as if they are marketed under an ANDA and classified as a non-innovator multiple source drug. Likewise, certain drugs approved under a paper NDA prior to the enactment of the Hatch-Waxman Amendments of 1984 or under certain types of literature-based 505(b)(2) NDA approvals after the Hatch-Waxman Amendments of 1984 might be more appropriately treated as if they were approved under an ANDA and classified as a non-innovator multiple source drug, depending on the unique facts and circumstances of the particular situation.

Id. at 5191. Under the rule, "[t]o the extent a manufacturer has previously reported a drug [like EpiPen] marketed under an NDA, other than an ANDA, as a non-innovator multiple source drug, or believes it has approval from CMS to do so, that manufacturer must submit materials and receive a written determination from CMS as described above pursuant to this final rule." Id. at 5192.

More recent agency guidance muddies the analysis, however. According to a May 2 CMS manufacturer release relating to the MDRP, "manufacturers may not rely upon previous communications from CMS regarding Drug Category reporting that were provided prior to the publication of the Final Rule to justify their classification of a drug marketed under an NDA as a non-innovator multiple source drug." (emphasis added). Notably, too, "the determination as to whether the narrow exception applies for the classification of the drug will depend on the drug itself and NDA at issue, not the active ingredient in the drug." Id.

We understand that Mylan is standing by the decision to classify EpiPen as a non-innovator drug and plans to apply for continued non-innovator status by the final rule's April 1, 2017 deadline. While the fate of Mylan's bid to avoid reclassifying EpiPen is uncertain, the controversy surrounding EpiPen likely will spur government investigations and enforcement actions over whether drug products reported as non-innovator multiple source drugs were fraudulently or improperly misclassified to lower rebates to Medicaid. We will report on developments in this area.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.